NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) on behalf of SIGA stockholders. Our investigation concerns whether SIGA has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On September 23, 2024, after market hours, SIGA disclosed that its Chief Medical Officer and Executive Vice President, Dr. Jay Varma, had been terminated from his position. On this news, SIGA’s stock price fell $0.42, or 5%, to close at $8.01 per share on September 24, 2024, thereby injuring investors.
Then, on September 25, 2024, a secretly recorded video surfaced online, revealing Varma detailing a media “spin” campaign to salvage TPOXX as a treatment for Monkeypox so that investors wouldn’t “dump the stock, thinking that the Company is worthless,” despite the admission that “in the United States, the risk [for Monkeypox] is very low.” On this news, SIGA’s stock price fell $1.26, or 15.7%, to close at $6.75 per share on September 25, 2024, thereby injuring investors further.
If you purchased or otherwise acquired SIGA shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
- Thermosome Receives U.S. Orphan Drug Designation for Lead Compound THE001, Expands Patent Estate - May 12, 2025
- Lead Service Line Replacement Cost Calculator (LSLRCC) Federal Trademark and Copyright Applications Filed by Environmental & Public Health International - May 12, 2025
- PageUp Unifies Brands to Strengthen Market Leadership and Enhance Customer Experience - May 12, 2025
